BioSpace News Archive

POXEL SA announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease.

Vico Therapeutics B.V., a neurology-focused genetic medicine company, announced the appointment of Scott Schobel, MD as chief medical officer.

Lumanity announced that it has expanded its pharmaceutical product launch capabilities, creating a technology-enabled, end-to-end launch excellence service offering.

Modular Medical Inc., a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, provided an update on its insulin pump product.

Henry Schein, Inc. announced the annual launch of its Practice Pink® program supporting nonprofit organizations dedicated to cancer research and prevention.

PACT Pharma, Inc. announced that it has entered into an agreement to sell select assets to AmplifyBio, a contract research organization focused on accelerating innovation across pharmaceutical modalities.

Eagle Pharmaceuticals, Inc. and Enalare Therapeutics Inc. (“Enalare”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to ENA-001 for the treatment of Apnea of Prematurity (“AoP”), a new chemical entity with a novel mechanism of action as a respiratory stimulant.

CollPlant Biotechnologies today announced that the Company’s Deputy CEO & Chief Financial Officer Eran Rotem will present a company overview at the Dawson James 7th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida.

LogicBio® Therapeutics, Inc., a pioneering clinical-stage genomic medicine company, announced that it has entered into a definitive agreement under which AstraZeneca Rare Disease will acquire LogicBio.

Kira Pharmaceuticals announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for KP104, a first-in-class bifunctional biologic that selectively and synergistically targets the alternative and terminal complement pathways.